These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20019814)

  • 41. Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to T cells.
    Giese S; Marsh M
    PLoS Pathog; 2014 Jul; 10(7):e1004189. PubMed ID: 24991932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.
    Jouvenet N; Neil SJ; Zhadina M; Zang T; Kratovac Z; Lee Y; McNatt M; Hatziioannou T; Bieniasz PD
    J Virol; 2009 Feb; 83(4):1837-44. PubMed ID: 19036818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
    Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
    Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tetherin and its viral antagonists.
    Kuhl BD; Cheng V; Wainberg MA; Liang C
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):188-201. PubMed ID: 21222046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BST-2 diminishes HIV-1 infectivity.
    Zhang J; Liang C
    J Virol; 2010 Dec; 84(23):12336-43. PubMed ID: 20861258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The great escape: viral strategies to counter BST-2/tetherin.
    Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
    PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
    Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging role of the host restriction factor tetherin in viral immune sensing.
    Hotter D; Sauter D; Kirchhoff F
    J Mol Biol; 2013 Dec; 425(24):4956-64. PubMed ID: 24075872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species.
    Sato K; Yamamoto SP; Misawa N; Yoshida T; Miyazawa T; Koyanagi Y
    Retrovirology; 2009 Jun; 6():53. PubMed ID: 19490609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beyond Tethering the Viral Particles: Immunomodulatory Functions of Tetherin (
    Tiwari R; de la Torre JC; McGavern DB; Nayak D
    DNA Cell Biol; 2019 Nov; 38(11):1170-1177. PubMed ID: 31502877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.
    Lv M; Wang J; Zhu Y; Wang X; Zuo T; Liu D; Zhang J; Wu J; Zhang H; Kong W; Yu X
    FEBS Lett; 2013 Jan; 587(1):37-43. PubMed ID: 23201263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of Tetherin Inhibition of Alphavirus Release.
    Wan JJ; Ooi YS; Kielian M
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
    Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
    J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
    Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments.
    Cole G; Simonetti K; Ademi I; Sharpe S
    Biochemistry; 2012 Jun; 51(25):5033-40. PubMed ID: 22667354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BST-2 restricts IAV release and is countered by the viral M2 protein.
    Hu S; Yin L; Mei S; Li J; Xu F; Sun H; Liu X; Cen S; Liang C; Li A; Guo F
    Biochem J; 2017 Feb; 474(5):715-730. PubMed ID: 28087685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
    Goffinet C; Allespach I; Homann S; Tervo HM; Habermann A; Rupp D; Oberbremer L; Kern C; Tibroni N; Welsch S; Krijnse-Locker J; Banting G; Kräusslich HG; Fackler OT; Keppler OT
    Cell Host Microbe; 2009 Mar; 5(3):285-97. PubMed ID: 19286137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.